Multiple sclerosis and neurotransmission

Biogenic Amines

Volumn 12, Issue 5, 1996, Pages 353-376

  Qureshi, G Ali ^a   Halawa, Ammar ^a   Baig, Shahid ^b   Siden, Åke ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b AGA KHAN UNIVERSITY HOSPITAL   (Pakistan)

Author keywords

Catecholamines; Cerebrospinal fluid; Cholecystokinin; Excitatory amino acids; Homocysteine; Multiple sclerosis; Neuropeptide Y; Nitrite; Vitamin B12

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 4 AMINOBUTYRIC ACID; 5 HYDROXYINDOLEACETIC ACID; ARGININE; ASPARTIC ACID; CHOLECYSTOKININ; CHOLECYSTOKININ OCTAPEPTIDE; CYANOCOBALAMIN; DOPAMINE; EXCITATORY AMINO ACID; GLUTAMIC ACID; HOMOCYSTEINE; HOMOVANILLIC ACID; MONOAMINE; NEUROPEPTIDE; NEUROPEPTIDE Y; NITRIC OXIDE; NITRITE; NORADRENALIN; SEROTONIN; TETRAGASTRIN; TRYPTOPHAN;

ADULT; ARTICLE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; NEUROTRANSMISSION; NORMAL HUMAN;

EID: 0010534586     PISSN: 01688561     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (91)

1. Albin, R.L. and Greenamyre, J.T. (1992) Alternative excitatoxic hypotheses. Neurology 42, 733-738.
2. Albus, M. (1988) Cholecystokinin.Prog.Neuro-Psychopharmacol & Biol.Psychiat. 12, S5-S21.
3. Allen, J.M., Gibson, S.J., Adrian, T.E., Polak, J.M. and Bloom, S.R. (1984) Neuropeptide Y in human spinal cord. Brain Res. 308, 145-148.
4. Allen, I. and Kirk, J. (1992) Demyelinating Disease In: Adams, J.H. and Dunchen, L.W. (eds) Greenfield neuropathology, 5th edition, Edward Arnold, London, pp 449-520.
5. Allen, I. and Brankin, B. (1993) Pathogenesis of Multiple sclerosis - The immune diathesis and the role of viruses. J.Neuropath.Expt.Neurology 52(2), 95-105.
6. Alom, J., Galard, R., Catalan, R., Castellanos, J.M., Schwartz, S. and Tolosa, E. (1990) cerebrospinal fluid neuropeptide Y in Alzheimer's disease. Eur.Neurol. 30, 207-210.
7. Andersson, P.B., Perry, V.H. and Gordon, S. (1992) Theacute inflammatory response to lipopolysaccharide in CNS parenchyma differs from that in other body tissues. Neurosci. 48, 169-186.
8. Baig S., Olsson O., Olsson T., Löve A., Jeansson S., Link H .(1989). Cells producing antibody to measles and herpes simplex virus in cerebrospinal fluid and blood of patients with multiple sclerosis and controls. Clin. Exp. Immunol. 78 , 390-395.
9. Baig S., Olsson T., Yu-Ping J., Höjeberg B., Cruz M., Link H. (1991). Multiple sclerosis: Cells secreting antibodies against myelin associate glycoprotein are present in CSF. Scand. J. Immunol. 33, 73-79.
10. Baig, S., Halawa, I. and Qureshi, G.A. (1991) HPLC as a tool in defination of abnormalities in monoamines and tryptophan metabolites in CSF from patients with neurological disorders Biomed.Chromatogr. 5, 108-112.
11. Baig, S.M. and Qureshi, G.A. (1995) Homocysteine and Vitamin B12 in Multiple Sclerosis. Biogenic Amine s 11(6), 479-485.
12. Bank, R.G.S., Henderson, J.R. and Pratt, J.M. (1968) Reactions of gases in solution. III Some reactions of Nitric oxide with transition metal complexes. J.Chem.Soc. (A) 3, 2886-90.
13. Beal, M.F. (1992a) Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illness?. Ann. Neurol 31, 119-130.
14. Beal M.F. (1992b) Mechanism of excitotoxicity in neurological disease, FASEB J. 6, 3338-3344.
15. Beal, M.F. (1995) Aging, Energy and oxidative stress in neurodegenerative disease. Ann.Neurol. 38, 357-366.
16. Bednar, I., Baig, S., Silberring, J., Stenfors, C., Södersten, P., Siden, Å. and Qureshi, G.A. (1996) Excitatory amino acids, monoamines, neuropeptide Y and CCK in cerebrospinal fluid of Parkinson patients. Biogenic Amines (in press).
17. Beinfeld, M.C. (1983) Cholecystokinin in Central nervous system : A minireview. Neuropeptides 3, 311-327.
18. Berrettini, W.H., Nurnberger, J.I. Jr. and Domaggio, D.A. (1986) Neuropeptide Y immunoreactivity in human cerebrospinal fluid. Peptides 7, 455-458.
19. Björklund, A. and Lindvall, O. (1984) Dopamine-containing systems in the CNS. In : Björklund, A. and Hökfelt, T. (eds). Handbook of Chemical neuroanatomy. Elsevier, Amsterdam, The Netherland.
20. Bondy, S.C., LeBele, C.P. (1993) The relationship between excitotoxicity and oxidative sress in the central nervous system. Free Rad. Biol.Med. 14,633-642.
21. Bradwejn, J. and DeMontigny, C. (1984) Benzodiazepines antagonise cholecystokinin-induced activation of rat hippocampal neurons. Nature 312, 363-364.
22. Chambers, D.T., Dewar, D., Graham, D.I., Brooks, D.N. and McCulloch, J. (1990) Differential alterations of cortical glutamatergic binding sites in senile dementia of Alzheimer type. Proc.Natn.Acad.Sci. USA 87, 1352-1356.
23. Chanarin I., Deacon R., Lumb M., Muir M., Perry J. (1988). Cobalamin folate interrations : A Critical Review. Blood 66,479-482.
24. Choi, D.W. (1988) Glutamate neurotoxicity and diseases of nervous system. Neuron 1, 623-634.
25. Choi, D.W. and Rothman, S.M. (1987) The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Ann.Rev.Neurosci, 13, 171-182.
26. Cooper, J.R., Bloom, F.E. and Roth, R.H. (1991) The biochemical basis of neuropharmacology. Oxford University Press, New York.
27. Coyle, J.T. and Puttfarcken, P. (1993) Oxidative stress, glutamate and neurodegenerative disorders. Science 262, 689-694.
28. Cowburn, R., Hardy, J., Roberts, P. and Briggs, R. (1988) Regional distribution of pre- and postsynaptic glutamatergic function in Alzheimer's disease. Brain Res. 452, 403-407.
29. Crellin R.F., Bottiglieri T., Reynolds E.H. (1990). Multiple sclerosis and macrocytosis. Acta. Neurol. Scand. 81, 388-91.
30. Davis, K., Kahn, R., Ko, G. and Davidson, M. (1991) Dopamine in schizophrenia : a review and reconceptaulization. Am.J.Phychiatry 148, 1474-1486.
31. Dawson, T.M., Dawson, V.L. and Snyder, S.H. (1992) A novel neuronal messager molecule in brain : The free radical, nitric oxide. Ann.Neurol. 32, 297-311.
32. Dawson, V.L. and Dawson, T.M. (1996) Free radicals and neuronal cell death. Cell Death and Differentiation 3, 71-78.
33. Deacon, R., Lamb, M. and Perry, J. (1978) Selective inactivation of vitamin B12 in rats by nitrous oxide. Lancet 2, 1023-24.
34. Dodd, P.R., Williams, S.H., Gundlach, A.L., Harper, P.A.W., Healy, P.J., Dennis, J.A. and Johnston, G.A.R. (1992) Glutamate and GABA neurotransmitter systems in the acute phase of Maple Syrup urine disease and citrullinemia encephalopathies in new born calves. J.Neurochem. 59, 582-590.
35. Dodd, P.R., Scott, H.L. and Wesrphalen, R.I. (1994) Excitotoxic mechanism in the pathogenesis of dementia. Neurochem.Int. 25, 203-219.
36. Drummond, J.T. and Methews, R.G. (1994) Nitrious oxide degradation by cobalamin-dependent synthase : Characterization of reactants and products in the activation reaction. Biochemistry 33, 3732-3741.
37. Everitt, B.J., Hökfelt, T, Terenius, L., Tatemoto, K., Mutt, V. and Goldstein, M. (1984) Differential co-existence of NPY-immunoreactivity with catecholamines in the central nervous system of the rat. Neuroscince , 11, 443-463.
38. Fernstrom, J.D. and Wurtman, R.J. (1972) Brain serotonin content : Physiological regulation of plasma neutral amino acids. Science 178, 414-416.
39. Garthwaite, J. (1991) Glutamate,Nitric oxide and cell-cell signalling in the nervous system. Trends Neurosci. 14, 60-67.
40. Gottfries, C. (1990) Brain monoamines and their metabolites in dementia. Acta Neurol.Scand. (Suppl) 129, 8-11.
41. Halawa, I., Baig, S. and Qureshi, G.A. (1991) Application of HPLC in defining the abnormalities in patients with aseptic meningitis. J. Biomed. Chromatogr., 5, 216-222
42. Halawa, A., Baig, S. and Qureshi, G.A. (1996) Amino acids and nitrite in ischemic brain stroke. Biogenic Amines 12 (1), 27-36.
43. Hall, C.A. (1990) Function of Vitamin B12 in the central nervous system as revealed by congenital detects. Amr.J.Hemalt. 34, 121-127.
44. Halliwell, B. (1992) Reactive oxygen species and the central nervous system. J.Neurochem. 59, 1609-1614.
45. Harro, J., Kiivet, R.A., Lang, A. and Vasar, E. (1990) Rats with anxious or non-anxious type of exploratory behavior differ in their brain CCK-8 and benzodiazepine receptor characterstic. Behav.Brain Res. 39, 63-71.
46. Heilig, M. and Widerlov, E. (1990) Neuropeptide Y: an overview of central distribution, functional aspects and possible involvement in neuropsychiatric illness. Acta Psychiatr.Scand. 8, 295-314.
47. Herkenham, M. (1987) Mismatches between neurotransmitter and receptor localizations in brain: observations and implications. Neuroscience, 23, 1-38.
48. Hyland K., Bottiglieri T .(1992). Measurement of total plasma and CSF homocysteine by fluorescence following HPLC and pre-column derivation with OPA. J. Chromatogr. 579, 55-62.
49. Hökfelt, T., Lundberg, J.M., Lagercrantz, H., Tatemoto, K., Mutt, V., Lindberg, J. Terenius, L., Everitt, B.J., Fuxe, K., Agnati, L. and Goldstein, M. (1983) Occurrence of neuropeptide Y (NPY)-like immunoreactivity in catecholamine neurons in human medulla oblongata. Neurosci. Lett. 36 , 217-222.
50. Ikeda T., Funikawa Y., Mashimoto T., Takahashi K. and Yamada M. (1990). Vitamin B12 levels in serum and CSF of people with Alzheimer disease. Acta. Psychiatr. Scand . 82, 327-329.
51. Kaku S., Tanaka M., Muramatsu M, Otomo S. (1994) Determination of nitrite by HPLC with EC: Measurement of Nitric oxide synthase activity in rat cerebellum cytosol, J.Biomed. Chromatogr. 8, 24-28.
52. Kang S.S. and Wong P.W.K. (1987). Norusis M. Homocysteinuri due to folate deficiency. Metabolism 36, 458-462.
53. Kermode, A.G., Thompson, A.J., Tofts, P., MacManus, D.G., Kendall, B.E., Kingsle, D.P., Moseley, I.F., Rudge, P. and McDonald, W.I. (1990) Breakdown of the blood-brain barrier procedees symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. Brain 113, 1477-1489.
54. Knight, J.A. (1995) Diseases related to oxygen-derived free radicals. Annal Clin.Lab.Sci. 25(2), 111-121.
55. Kontos, H.A. (1989) Oxygen radicals in CNS damage. Chem.Biol.Interact. 72, 229-236.
56. Lassmann, H., Zimprich, F., Rössler, K. and Vass, K. (1991) Inflammation in the nervous sytem. Basic mechanisms and immunological concepts. Rev.Neurol. 147, 763-781.
57. Lees, G.J. (1993) Contributory mechanisms in the causation of neurodegenerative disorders. Neurosci. 54, 287-291.
58. Lindenbaum J., Healton, E.B. and Savage, D.G. (1988) Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. J.Eng.J.Med.318, 1720-1728.
59. Lofton-Cazal, M., Pietri, S., Culcasi, M. and Bockaert, J. (1993) NMDA-dependent superoxide production and neurotoxicity. Nature 364, 535-537.
60. Maeda, K., Yasuda, M., Kaneda, H., Maeda, S. and Yamadori, A. (1994) CSF Neuropeptide Y and Somatostatin-like immunoreactivities in man. Neuropeptide 27, 323-332.
61. Maragos, W.F., Greenmayre, T., Penny, J.B. and Young, A.B. (1987) Glutamate dysfunction in Alzheimer disease : An hypothesis. Trend Neurosci. 10, 65-68.
62. Male, D., Pryce, G. and Rahman, J. (1990) Comparison of the immunological properties of rat cerebral and aortic endothelium. J.Neuroimmunol. 30, 161-168.
63. McKhan, G.M. (1987) In: Aldelman, G. (eds) Encyclopedia of Neuroscience, volume 1, Birkhäuser, Boston,USA, pp 705-706.
64. Metz, J. (1992) Cobalamin deficiency and the pathogensis of nervous system disease. Ann.Ren.Nub. 12, 59-79.
65. Moor, A.C.M., Devries, H.E., DeBoer, A.G. and Breimer, D.D. (1994) The blood-brain barrier and multiple sclerosis. Biochem.Pharm. 47, 1717-1724.
66. Olanow, C.W. and Arendash, G.W. (1994) Metal and free radicals in neurodegeneration. Current opinion in Neurology 7, 548-558.
67. Olney, J.W. (1978) Neurotoxicity of excitatory amino acids In: McGeer, E.G., Olney, J.W. and McGeer, P.L. (eds) Kainic acid as a tool in Neurobiology. Raven Press, New York, pp 37-69.
68. Poser, C.M. (1993) The pathogenesis of multiple sclerosis. Additional consideration. J.Neurol.Sci. 115, 3-15.
69. Poster, C. (1986) Pathogenesis of Multiple Sclerosis. Acta Neuropathol. 71, 1-10.
70. Qureshi, G.A. and Baig, S.M. (1988) Quantitation of amino acids in biological samples by HPLC. J.Chromatogr. 459, 237-244.
71. Qureshi, G.A. and Baig, S. (1993a) Role of neurotransmitters amino acids in multiple sclerosis in exacerbation, remission, and progressive course.Biogenic Amines 10, 39-48.
72. Qureshi, G.A., Bednar, I., Min, Q., Södersten, P., Silberring, J., Nyberg, F. and Thörnwall, M. (1993b) Quantitation and identification of two cholecystokinin peptides, CCK-4 and CCK-8s in rat brain by HPLC and fast atom bombardment mass spectroscopy. Biomed.Chromatogr. 7, 251-255.
73. Qureshi, G.A., Baig, S., Bednar, I., Södersten, P., Forsberg, G. and Siden, Å. (1995) Increased cerebrospinal fluid concentration of nitrite in Parkinson's disease. NeuroReport 6, 1642-1644.
74. Regland, B. (1991) Vitamin B12 deficiency in dementia disorders, Ph.D. thesis, Gothenborg University, Gothenborg, Sweden.
75. Reynolds E.H., Linnell J.C. and Faludy J.E. (1991). Multiple sclerosis associated with vitamin B12 deficiency. Arch. Neurol. 48, 808-811.
76. Rochelle, L.G., Morana, S.J., Kruszyna, H., Russel, M.A., Wilcox, D.E. and Smith, R.P. (1995). Interactions between hydroxocobalamin and nitric oxide: Evidence for redox reaction between nitric oxide and reduced cobalamin and reversible NO binding to oxidized cobalamin.J.Pharm & Exp. Ther.275,48-52.
77. Sayetta, R.B. (1986) Theories of the etiology of Multiple Sclerosis: A critical review. J.Clin.Lab.Immunol. 21, 55-70.
78. Schumacher G.A., Becke G., Kibler R.E., Kurland L., Kurtzke J., McDowell F., Nogler B., Sibley W., Tourtellotte W.W., Willmon T. (1965). Problem on the experimental trails of therapy in Multiple Sclerosis : report by a panel on the evaluation of experimental trails of therapy in Multiple Sclerosis.Ann. N.Y. Acad. Sci. 122, 552-558.
79. Shevell M.I., Rosenblatt D.S. (1992). The Neurology of Cobalamin. Can. J. Neurol.Sci. 19, 472-486.
80. Susuki, Y., Sato, S. and Susuki, S. (1989) Increased neuropeptide Y concentrations in cerebrosphinal fluid from patients with aneurysmal subarachnoid haemorrhage. Stroke 20, 1680-1684.
81. Starke, K., Göthert, M. and Kilbinger, H. (1989) Modulation of neurotransmitter release by presynaptic autoreceptors. Physiol. Rev., 69, 864-989.
82. Theodorsson, N.E., Hemsen, A. and Lundberg, J.M. (1985) Radioimmunoassay for neuropeptide Y (NPY) : chromatographic characterization of immunoreactivity in plasma and tissue extracts. Scand.J.Clin,Lab.Invest. 45, 355-365.
83. Thompson, A.J., Kermode, A.G., Macmanus, D.G., Kingsley, D.P.E., Kendall, B.E., Moseley, I and Mcdonald, W.I. (1989).Pathogenesis of progressive multiple sclerosis. Lancet,i, 1322-1323.
84. Tourtelotte, W.W. and Ma, B.I. (1978) Multiple sclerosis : the blood-brain barrier and the measurement of de novo central nervous system IgG synthesis. Neurology 28, 76-83.
85. Tymiaski, M., Charlton, M.P. and Carlen, P.L. (1993) Source specificity of early Calcium neurotoxicity in cultured embryonic spinal neurons. J.Neurosci. 13,2085-2104.
86. Walker, J.E. (1983) Glutamate,GABA and CNS diseases. Neurochem.Res. 8, 521-550.
87. Watkins D., Rosenblatt D.S. (1989). Functional methionine synthase deficiency: Clinical and biochemical heterogeneity. Amr.J.Med. Genet. 34, 427-430.
88. Wester, P., Bergström, U. and Eriksson, A. (1990) Venticular cerebrospinal fluid monoamine transmitter and metabolite concentrations refect human brain neurochemistry in autopsy cases. J.Neurochem. 54, 1148-1156.
89. Widerlöv, E., Lindström, H., Wahlestedt, C. and Ekman, R. (1988) NPY and PYY as possible cerebrospinal marker for major depression and schizophrenia respectively. J.Psychiatr.Res. 22, 69-79.
90. Yagiela, J.A. (1991) Health Hazards and nitric oxide : a time for reappriasal. Anesth.Prog. 38, 1-11.
91. Yu, B.P. (1994) Cellular defences against damage from reactive oxygen species. Physiol. Rev. 74, 139-162.